Horizon Pharma to Host Corporate Update Meeting on March 27, 2014

Horizon Pharma to Host Corporate Update Meeting on March 27, 2014 
DEERFIELD, IL -- (Marketwired) -- 03/24/14 --  Horizon Pharma, Inc.
(NASDAQ: HZNP) will host a Corporate Update Meeting on Thursday,
March 27, 2014 at 7:30 a.m. Eastern Time in New York, NY. 
The meeting will be webcast live and may be accessed by visiting
Horizon's website at http://ir.horizon-pharma.com. A replay of the
webcast will be available for 10 business days.  
About Horizon Pharma 
Horizon Pharma, Inc. is a commercial stage, specialty pharmaceutical
company that markets DUEXIS(R), VIMOVO(R) and RAYOS(R)/LODOTRA(R),
which target unmet therapeutic needs in arthritis, pain and
inflammatory diseases. The Company's strategy is to develop, acquire
or in-license additional innovative medicines where it can execute a
targeted commercial approach among specific target physicians such as
primary care physicians, orthopedic surgeons and rheumatologists,
while taking advantage of its commercial strengths and the
infrastructure the Company has put in place. For more information,
please visit www.horizonpharma.com. 
Additional Information and Where to Find It  
In connection with a proposed transaction with Vidara Therapeutics
International Ltd., Horizon and Vidara will be filing documents with
the SEC, including the filing by Horizon of a preliminary and
definitive proxy statement/prospectus relating to the proposed
transaction and the filing by Vidara of a registration statement on
Form S-4 that will include the proxy statement/prospectus relating to
the proposed transaction. After the registration statement has been
declared effective by the SEC, a definitive proxy
statement/prospectus will be mailed to Horizon stockholders in
connection with the proposed transaction. INVESTORS AND SECURITY
HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND
THE RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS WHEN THEY
BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION
ABOUT HORIZON, VIDARA AND THE PROPOSED TRANSACTION. Investors and
security holders may obtain free copies of these documents (when they
are available) and other related documents filed with the SEC at the
SEC's web site at www.sec.gov, by directing a request to Horizon's
Investor Relations department at Horizon Pharma, Inc., Attention:
Investor Relations, 520 Lake Cook Road, Suite 520, Deerfield, IL
60015 or to Horizon's Investor Relations department at 224-383-3000
or by email to investor-relations@horizonpharma.com. Investors and
security holders may obtain free copies of the documents filed with
the SEC on Horizon's website at www.horizonpharma.com under the
heading "Investors" and then under the heading "SEC Filings."  
Horizon and its directors and executive officers and Vidara and its
directors and executive officers may be deemed participants in the
solicitation of proxies from the stockholders of Horizon in
connection with the proposed transaction. Information regarding the
special interests of these directors and executive officers in the
proposed transaction will be included in the proxy
statement/prospectus described above. Additional information
regarding the directors and executive officers of Horizon is also
included in Horizon's Annual Report on Form 10-K for the year ended
December 31, 2013, which was filed with the SEC on March 13, 2014.
These documents are available free of charge at the SEC's web site at
www.sec.gov and from Investor Relations at Horizon as described
above.  
This communication does not constitute an offer to sell, or the
solicitation of an offer to sell, or the solicitation of an offer to
subscribe for or buy, any securities nor shall there be any sale,
issuance or transfer of securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such jurisdiction. 
Contacts
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
investor-relations@horizonpharma.com  
Ami Bavishi
abavishi@burnsmc.com 
212-213-0006, ext. 344
 
 
Press spacebar to pause and continue. Press esc to stop.